Cadefrecitinib
Small molecule
Also known as GLPG3667
Evidence outlook · program status
Discontinued (2026-11-11), as a strategic decision by the sponsor
Lakefront Biotherapeutics discontinued the GLPG3667 (cadefrecitinib) programme after discussions with potential partners. The trials below are preserved as the program's evidence history; no evidence signal is assigned to a program the sponsor has stopped.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
GALARISSO NCT05695950 · Dermatomyositis GALARISSO was a randomised, double-blind, placebo-controlled phase 2 study in 40 adults with dermatomyositis, who took GLPG3667 150 mg once daily or placebo on top of standard care for 24 weeks. The primary endpoint was the Total Improvement Score at week 24. GLPG3667 improved the score by 14.26 points more than placebo, with p=0.0848. The study set its significance threshold in advance at 10% (alpha=0.1) instead of the usual 5%, so the primary endpoint was met under that rule. The figures come from the company's press release; no peer-reviewed paper is available yet. Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence. Registry: NCT05695950 | 2 | Total improvement score [TIS] according to the American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) criteria (Week 24) 2025-10-13 | Primary, Total Improvement Score at week 24: GLPG3667 150 mg (n=21) vs placebo (n=19), difference 14.26 points (p=0.0848), met against the prespecified significance threshold of alpha=0.1. | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 2 (2)
What this study did
What this study did
Phase 1 (6)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Competitive landscape
Other TYK2 drugs
deucravacitinib, Envudeucitinib, Fadeucravacitinib, HS-10374, Nomelcitinib (D-2570) and 8 more. Compare all 14 TYK2 drugs
This mechanism is crowded: 13 other tracked programmes target it, 13 of them ahead of this one.
This drug's own stage for Dermatomyositis: Discontinued. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Cadefrecitinib: this drug | Discontinued | Small molecule | TYK2 | not yet graded | No reviewed efficacy summary in this indication | |
| Brepocitinib (Lisraya) | Approved | Small molecule | TYK2/JAK1 | not yet graded | No reviewed efficacy summary in this indication | |
| Repository Corticotropin (Acthar Gel) | Approved | Peptide | Melanocortin receptors (primarily MC2R on the adrenal cortex), Melanocortin 2 receptor (MC2R) (agonist) | not yet graded | No reviewed efficacy summary in this indication | |
| PF-06823859 | Phase 3 | Monoclonal antibody | Interferon beta (IFN-beta) | not yet graded | No reviewed efficacy summary in this indication | |
| Descartes-08 | Phase 1/2 | Cell therapy | BCMA (B-cell maturation antigen) | not yet graded | No reviewed efficacy summary in this indication | |
| A-005 | Phase 1(overall) | Small molecule | TYK2 | not yet graded(overall) | No reviewed efficacy summary in this indication |
Upcoming events
No upcoming readouts on record for this asset.
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent